Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join


Sep 07, 2021 7:00 PM - Sep 10, 2021 12:30 AM

4051 Basel, Switzerland

Pharmacovigilance Strategies Workshop

Navigating the changing PV landscape in your daily work. Anniversary edition: 5 years

Session 3: Practical approaches and innovations in Risk Minimisation and Pharmacovigilance activities

Session Chair(s)

Wendy  Huisman, PharmD

Wendy Huisman, PharmD


Vigifit, Netherlands

Bianca  Mulder, PharmD, MPharm, MSc

Bianca Mulder, PharmD, MPharm, MSc

Pharmacovigilance Assessor

Medicines Evaluation Board, Netherlands

GVP Module XVI provides guidance for the use of additional risk minimisation measures including the selection of tools and their evaluation of their effectiveness. However, throughout Europe the implementation of additional risk minimisation measures, such as educational material, might vary between countries. Furthermore, over the last years we have seen several examples in which different companies marketing the same active substance are working in a consortium to improve the harmonization of these materials and to set up joint Drug Utilisation Studies as is also encouraged in the update of GVP Module XVI. This session will explore examples and points to consider on both topics to help stimulate discussion. There will be perspectives from Industry and the Dutch Regulatory Agency. In addition to hearing from the speakers, attendees will be encouraged to share their experience as part of the Panel Discussion


Giovanna  Ferrari, PhD

Gravitate Health Background and the Potential for Pharmacovigilance (E.g: Risk Minimization): Giovanna Ferrari, PhD

Regional Labelling Lead, Senior Director

Pfizer Ltd, United Kingdom

Gabrielle  Amselem, PharmD

Harmonisation of Educational Material Between Member States : Gabrielle Amselem, PharmD

Dir, Pharmacovigilance Excellence Expert

Alexion, AstraZeneca Rare Disease, France

Stephanie  Tcherny- Lessenot, MD, MPH, MSc

Experience when Working in a Consortium : Stephanie Tcherny- Lessenot, MD, MPH, MSc

Head of Benefit-Risk Evaluation, Epidemiology & Benefit-Risk Evaluation

Sanofi, France

Inge  Zomerdijk, MSc

Experience when Working in a Consortium : Inge Zomerdijk, MSc

Pharmacovigilance Assessor

Medicines Evaluation Board (MEB), Netherlands

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.